Drug combinations with HDAC inhibitors in antitumor therapy

Noemi Arrighetti, Cristina Corno, Laura Gatti

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The treatment of tumor cells with HDAC inhibitors (HDACi) induces a range of effects including apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune response, and altered angiogenesis. The single-agent activities of several HDACi have been tested in preclinical and clinical studies and are currently the subject of ongoing clinical trials. Although HDACi have been shown to be effective as a single agent against a defined subset of hematological tumors, less convincing results have been found in the treatment of solid tumors. Since current clinical trials of single-agent HDACi showed limited efficacy, in this review we focus on drug combinations including HDACi with conventional chemotherapeutic agents and novel targeted agents. Particular emphasis has been devoted to combinations effective in solid tumors and to combinations between HDACi and immunotherapies. An outline of novel combination strategies, including a new generation of more potent and specific HDACi (e.g., compounds with adamantine and noradamantane as scaffolds) as well as chemical hybrid molecules, has been provided. The paradoxical role of HDACs as tumor suppressors in developing tumors and as therapeutic targets in established neoplasms has also been considered.

Original languageEnglish
Pages (from-to)83-117
Number of pages35
JournalCritical Reviews in Oncogenesis
Volume20
Issue number1-2
DOIs
Publication statusPublished - 2015

Fingerprint

Histone Deacetylase Inhibitors
Drug Combinations
Neoplasms
Therapeutics
Clinical Trials
Cell Aging
Cell Cycle Checkpoints
Immunotherapy
Apoptosis

Keywords

  • Antitumor therapy
  • Drug combination
  • HDAC inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Drug combinations with HDAC inhibitors in antitumor therapy. / Arrighetti, Noemi; Corno, Cristina; Gatti, Laura.

In: Critical Reviews in Oncogenesis, Vol. 20, No. 1-2, 2015, p. 83-117.

Research output: Contribution to journalArticle

@article{f4307c07502548f38272a7862a516497,
title = "Drug combinations with HDAC inhibitors in antitumor therapy",
abstract = "The treatment of tumor cells with HDAC inhibitors (HDACi) induces a range of effects including apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune response, and altered angiogenesis. The single-agent activities of several HDACi have been tested in preclinical and clinical studies and are currently the subject of ongoing clinical trials. Although HDACi have been shown to be effective as a single agent against a defined subset of hematological tumors, less convincing results have been found in the treatment of solid tumors. Since current clinical trials of single-agent HDACi showed limited efficacy, in this review we focus on drug combinations including HDACi with conventional chemotherapeutic agents and novel targeted agents. Particular emphasis has been devoted to combinations effective in solid tumors and to combinations between HDACi and immunotherapies. An outline of novel combination strategies, including a new generation of more potent and specific HDACi (e.g., compounds with adamantine and noradamantane as scaffolds) as well as chemical hybrid molecules, has been provided. The paradoxical role of HDACs as tumor suppressors in developing tumors and as therapeutic targets in established neoplasms has also been considered.",
keywords = "Antitumor therapy, Drug combination, HDAC inhibitors",
author = "Noemi Arrighetti and Cristina Corno and Laura Gatti",
year = "2015",
doi = "10.1615/CritRevOncog.2014012378",
language = "English",
volume = "20",
pages = "83--117",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "1-2",

}

TY - JOUR

T1 - Drug combinations with HDAC inhibitors in antitumor therapy

AU - Arrighetti, Noemi

AU - Corno, Cristina

AU - Gatti, Laura

PY - 2015

Y1 - 2015

N2 - The treatment of tumor cells with HDAC inhibitors (HDACi) induces a range of effects including apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune response, and altered angiogenesis. The single-agent activities of several HDACi have been tested in preclinical and clinical studies and are currently the subject of ongoing clinical trials. Although HDACi have been shown to be effective as a single agent against a defined subset of hematological tumors, less convincing results have been found in the treatment of solid tumors. Since current clinical trials of single-agent HDACi showed limited efficacy, in this review we focus on drug combinations including HDACi with conventional chemotherapeutic agents and novel targeted agents. Particular emphasis has been devoted to combinations effective in solid tumors and to combinations between HDACi and immunotherapies. An outline of novel combination strategies, including a new generation of more potent and specific HDACi (e.g., compounds with adamantine and noradamantane as scaffolds) as well as chemical hybrid molecules, has been provided. The paradoxical role of HDACs as tumor suppressors in developing tumors and as therapeutic targets in established neoplasms has also been considered.

AB - The treatment of tumor cells with HDAC inhibitors (HDACi) induces a range of effects including apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune response, and altered angiogenesis. The single-agent activities of several HDACi have been tested in preclinical and clinical studies and are currently the subject of ongoing clinical trials. Although HDACi have been shown to be effective as a single agent against a defined subset of hematological tumors, less convincing results have been found in the treatment of solid tumors. Since current clinical trials of single-agent HDACi showed limited efficacy, in this review we focus on drug combinations including HDACi with conventional chemotherapeutic agents and novel targeted agents. Particular emphasis has been devoted to combinations effective in solid tumors and to combinations between HDACi and immunotherapies. An outline of novel combination strategies, including a new generation of more potent and specific HDACi (e.g., compounds with adamantine and noradamantane as scaffolds) as well as chemical hybrid molecules, has been provided. The paradoxical role of HDACs as tumor suppressors in developing tumors and as therapeutic targets in established neoplasms has also been considered.

KW - Antitumor therapy

KW - Drug combination

KW - HDAC inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84922775646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922775646&partnerID=8YFLogxK

U2 - 10.1615/CritRevOncog.2014012378

DO - 10.1615/CritRevOncog.2014012378

M3 - Article

C2 - 25746106

AN - SCOPUS:84922775646

VL - 20

SP - 83

EP - 117

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 1-2

ER -